Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial

被引：0

作者：

Gladman, Dafna D. ^{[1
]}

Rigby, William ^{[2
]}

Azevedo, Valderilio F. ^{[3
,4
,5
]}

Behrens, Frank ^{[6
]}

Blanco, Ricardo ^{[7
]}

Kaszuba, Andrzej ^{[8
]}

Kudlacz, Elizabeth ^{[9
]}

Wang, Cunshan ^{[9
]}

Menon, Sujatha ^{[9
]}

Hendrikx, Thijs ^{[10
]}

Kanik, Keith S. ^{[9
]}

机构：

[1] Univ Toronto, Toronto, ON, Canada

[2] Dartmouth Hitchcock Med Ctr, Rheumatol, Lebanon, NH 03766 USA

[3] Univ Fed Parana, Curitiba, Parana, Brazil

[4] Edumed Hlth Res Ctr, Curitiba, Parana, Brazil

[5] Biotech, Curitiba, Parana, Brazil

[6] Goethe Univ Frankfurt, Frankfurt, Germany

[7] Hosp Univ Marques de Valdecilla, IDIVAL, Rheumatol, Santander, Spain

[8] Specialstyczne Gabinety Lerkarskie DERMED, Lodz, Poland

[9] Pfizer Inc, Groton, CT 06340 USA

[10] Pfizer Inc, Collegeville, PA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

10L

引用

页数：5

共 50 条

[21] Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Takeuchi, Tsutomu
Tanaka, Yoshiya
Tanaka, Sakae
Kawakami, Atsushi
Iwasaki, Manabu
Rokuda, Mitsuhiro
Izutsu, Hiroyuki
Ushijima, Satoshi
Kaneko, Yuichiro
Shiomi, Teruaki
Yamada, Emi
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[22] EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
Hassanien, M.
Moshrif, A.
Hetta, H.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 34 - 35
[23] Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Deodhar, Atul
Gottlieb, Alice B.
Boehncke, Wolf-Henning
Dong, Bin
Wang, Yuhua
Zhuang, Yanli
Barchuk, William
Xu, Xie L.
Hsia, Elizabeth C.
LANCET, 2018, 391 (10136): : 2213 - 2224
[24] DESIGNING A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF GUSELKUMAB DOSING INTERVAL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION
Ogdie, A.
Merola, J. F.
Mease, P. J.
Ritchlin, C. T.
Scher, J. U.
Chan, D.
Chakravarty, S. D.
Langholff, W.
Choi, O.
Krol, Y.
Rowland, K.
Gottlieb, A. B.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1567 - 1568
[25] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate, in Patients with Active Rheumatoid Arthritis with An Inadequate Response to Tumor Necrosis Factor-Inhibitors: A 6-Month Phase 3 Study.
Burmester, Gerd-Ruediger
Blanco, R.
Charles-Schoeman, C.
Wollenhaupt, J.
Zerbini, C. A. F.
Benda, B.
Gruben, D.
Wallenstein, G.
Krishnaswami, S.
Zwillich, S. H.
Koncz, T.
Bradley, J. D.
Mebus, C. A.
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S279 - S279
[26] Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
McInnes, Iain B.
Kavanaugh, Arthur
Gottlieb, Alice B.
Puig, Lluis
Rahman, Proton
Ritchlin, Christopher
Brodmerkel, Carrie
Li, Shu
Wang, Yuhua
Mendelsohn, Alan M.
Doyle, Mittie K.
LANCET, 2013, 382 (9894): : 780 - 789
[27] Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial
Lunzer, R.
JOURNAL FUR MINERALSTOFFWECHSEL, 2013, 20 (04): : 175 - 176
[28] Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Deodhar, Atul
Poddubnyy, Denis
Pacheco-Tena, Cesar
Salvarani, Carlo
Lespessailles, Eric
Rahman, Proton
Jarvinen, Pentti
Sanchez-Burson, Juan
Gaffney, Karl
Lee, Eun Bong
Krishnan, Eswar
Santisteban, Silvia
Li, Xiaoqi
Zhao, Fangyi
Carlier, Hilde
Reveille, John D.
Antolini, Christopher
Azevedo, Valderilio
Barkham, Magnus
Rodriguez, Aaron Alejandro Barrera
Berman, Alberto
Blicharski, Tomasz
Brzezicki, Jan
Burmester, Gerd
Carrio, Judith
Collantes, Eduardo
Combe, Bernard
Cons-Molina, Fidencio
Cortes-Maisonet, Gregorio
Dudek, Anna
Barragan, Sergio Duran
Elkayam, Ori
Flint, Kathleen
Galeazzi, Mauro
Gaylis, Norman
Goddard, David
Fernandez, Carlos Gonzalez
Goupille, Philippe
Masmitja, Jordi Gratacos
Greenwald, Maria
Gremese, Elisa
Hong, Seung Jae
Howell, Mary
Hrycaj, Pawel
Ince, Akgun
Ju, Ji Hyeon
Kaine, Jeffrey
Kang, Seong Wook
Keiserman, Mauro
Kim, Tae-Hwan
ARTHRITIS & RHEUMATOLOGY, 2019, 71 (04) : 599 - 611
[29] EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Gladman, D. D.
Mease, P. J.
Bird, P.
Soriano, E.
Chakravarty, S. D.
Shawi, M.
Xu, S.
Quinn, S.
Gong, C.
Leibowitz, E.
Tam, L. S.
Helliwell, P.
Kavanaugh, A.
Deodhar, A.
Ostergaard, M.
Baraliakos, X.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1574 - 1575
[30] Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Nash, Peter
Kirkham, Bruce
Okada, Masato
Rahman, Proton
Combe, Benard
Burmester, Gerd-Ruediger
Adams, David H.
Kerr, Lisa
Lee, Chin
Shuler, Catherine L.
Genovese, Mark
LANCET, 2017, 389 (10086): : 2317 - 2327

← 1 2 3 4 5 →